Walters: Welch Pleased After Meeting With Trump | Off Message

Walters: Welch Pleased After Meeting With Trump


Congressman Peter Welch - JOHN WALTERS
  • John Walters
  • Congressman Peter Welch

When approaching the self-proclaimed Master of the Deal, it’s best to offer him a chance to play dealmaker.

That’s what Congressman Peter Welch (D-Vt.) took away from a Wednesday meeting with President Donald Trump. The subject: a bill championed by Welch and Congressman Elijah Cummings (D-Md.) that would allow the federal government to negotiate lower drug prices for the Medicare program, which is currently forbidden by federal law.

“President Trump was knowledgeable and enthusiastic about this,” Welch reported. “He was not having staff whispering in his ear telling him what was going on. This was him totally in control and vividly aware of how expensive these prescription drugs are.”

The Oval Office sit-down included Welch, Cummings, and Dr. Redonda Miller, president of the Johns Hopkins Hospital, as well as Health and Human Services Secretary Tom Price, a former Georgia congressman.

Welch and Cummings have introduced the same legislation for eight years, and always run into what Welch called a “stone wall of resistance” from House Republicans.

When Price was serving in Congress, he was one of those devout stonewallers. He has also faced ethical questions about some very profitable trades in health care stocks he made when he had access to inside information as a member of a key House subcommittee.

It must have made Price a bit uncomfortable to hear his boss praising the idea. And Welch didn’t shy away from pointing out the discrepancy.

“I mentioned that Secretary Price had always been resistant to this when he was my colleague in the House,” Welch said, “so the president asked Price about that, and he said he’s against price fixing, price setting. And the president seemed undeterred by that, because I pointed out that price negotiation is what you do between a willing buyer and a willing seller.”

Welch called it “surprising” that Republicans oppose free-market dealmaking in the case of drug prices. “And the president said it’s probably because Big Pharma is very powerful in lobbying and campaign contributions,” Welch concluded. “So he gets that.”

Welch left the session optimistic, but with eyes wide open. “The proof will be, do we get a bill passed?” he said. “But bottom line, our only chance to succeed is to have his support.”

At the end of the meeting, Trump handed Welch’s and Cummings’ bill to Secretary Price with instructions to provide an official response. One hopes that Price didn’t find a convenient shredder on his way out of the Oval Office.